Rationale, design and baseline characteristics of the Microbiome and Insulin Longitudinal Evaluation Study (MILES).
insulin resistance
insulin secretion
type 2 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
09
04
2020
revised:
06
07
2020
accepted:
16
07
2020
pubmed:
21
7
2020
medline:
25
6
2021
entrez:
21
7
2020
Statut:
ppublish
Résumé
To investigate the role of the gut microbiome in regulating key insulin homeostasis traits (insulin sensitivity, insulin secretion and insulin clearance) whose dysfunction leads to type 2 diabetes (T2D). The Microbiome and Insulin Longitudinal Evaluation Study (MILES) focuses on African American and non-Hispanic white participants aged 40-80 years without diabetes. Three study visits are planned (at baseline, 15 and 30 months). Baseline measurements include assessment of the stool microbiome and administration of an oral glucose tolerance test, which will yield indexes of insulin sensitivity, insulin secretion and insulin clearance. The gut microbiome profile (composition and function) will be determined using whole metagenome shotgun sequencing along with analyses of plasma short chain fatty acids. Additional data collected include dietary history, sociodemographic factors, health habits, anthropometry, medical history, medications and family history. Most assessments are repeated 15 and 30 months following baseline. After screening 875 individuals, 129 African American and 224 non-Hispanic white participants were enrolled. At baseline, African American participants have higher blood pressure, weight, body mass index, waist and hip circumferences but similar waist-hip ratio compared with the non-Hispanic white participants. On average, African American participants are less insulin-sensitive and have higher acute insulin secretion and lower insulin clearance. The longitudinal design and robust characterization of potential mediators will allow for the assessment of glucose and insulin homeostasis and gut microbiota as they change over time, improving our ability to discern causal relationships between the microbiome and the insulin homeostasis traits whose deterioration determines T2D, setting the stage for future microbiome-directed therapies to prevent and treat T2D.
Identifiants
pubmed: 32687239
doi: 10.1111/dom.14145
pmc: PMC8444996
mid: NIHMS1695381
doi:
Substances chimiques
Blood Glucose
0
Insulin
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1976-1984Subventions
Organisme : USDA/ARS
ID : 58-3092-5-001
Pays : International
Organisme : NCATS NIH HHS
ID : UL1 TR001420
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001881
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK063491
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK109588
Pays : United States
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
PLoS One. 2013 Nov 13;8(11):e80476
pubmed: 24236183
J Womens Health Gend Based Med. 1999 Jul-Aug;8(6):805-13
pubmed: 10495261
Diabetes Care. 2006 Jun;29(6):1263-8
pubmed: 16732006
Diabetes Care. 2010 Jul;33(7):e93
pubmed: 20587713
Scand J Gastroenterol. 1997 Sep;32(9):920-4
pubmed: 9299672
Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1709-15
pubmed: 17895288
Sci Transl Med. 2019 Apr 24;11(489):
pubmed: 31019023
BMJ Open Diabetes Res Care. 2019 Nov 24;7(1):e000825
pubmed: 31803485
Nature. 2013 Jun 6;498(7452):99-103
pubmed: 23719380
Nat Rev Endocrinol. 2015 Oct;11(10):577-91
pubmed: 26260141
Nature. 2012 Jun 13;486(7402):207-14
pubmed: 22699609
Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31
pubmed: 31862745
Science. 2013 Jul 5;341(6141):1237439
pubmed: 23828941
J Hepatol. 2014 Apr;60(4):824-31
pubmed: 24316517
Nature. 2006 Dec 21;444(7122):1027-31
pubmed: 17183312
J Clin Gastroenterol. 2011 Feb;45(2):149-52
pubmed: 20661154
Gastroenterology. 2012 Oct;143(4):913-6.e7
pubmed: 22728514
Am J Physiol Endocrinol Metab. 2011 Aug;301(2):E402-8
pubmed: 21632466
Curr Nutr Rep. 2020 Jun;9(2):83-93
pubmed: 32157661
Nature. 2010 Mar 4;464(7285):59-65
pubmed: 20203603
Nature. 2015 Dec 10;528(7581):262-266
pubmed: 26633628
Nature. 2014 Jan 23;505(7484):559-63
pubmed: 24336217
Diabetologia. 2006 Dec;49(12):2824-7
pubmed: 17028899
Eur J Clin Nutr. 2012 Jan;66(1):53-60
pubmed: 21811294
Diabet Med. 1994 Oct;11(8):755-62
pubmed: 7851069
Gut. 2016 May;65(5):740-8
pubmed: 26657899
Nutr Diabetes. 2015 Jun 15;5:e159
pubmed: 26075636
Nature. 2012 Oct 4;490(7418):55-60
pubmed: 23023125
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14691-6
pubmed: 20679230
J Physiol Biochem. 2016 Jun;72(2):121-31
pubmed: 26660757
Diabetes. 2000 Dec;49(12):2116-25
pubmed: 11118015
Br J Nutr. 2015 Sep 28;114(6):899-907
pubmed: 26259632
J Clin Invest. 2007 Dec;117(12):4034-43
pubmed: 17992256
Am J Epidemiol. 2009 Feb 15;169(4):444-54
pubmed: 19075250
Sci Rep. 2015 Nov 17;5:16350
pubmed: 26572876
Nature. 2013 Aug 29;500(7464):541-6
pubmed: 23985870
BMJ Open Diabetes Res Care. 2019 May 28;7(1):e000657
pubmed: 31245008
Benef Microbes. 2014 Mar;5(1):33-43
pubmed: 24533976
Diabetes. 2009 May;58(5):1212-21
pubmed: 19223598